{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T14:36:36Z","timestamp":1785594996094,"version":"3.56.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2020,3,24]],"date-time":"2020-03-24T00:00:00Z","timestamp":1585008000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,3,24]],"date-time":"2020-03-24T00:00:00Z","timestamp":1585008000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Drugs Ther"],"published-print":{"date-parts":[[2020,6]]},"abstract":"Abstract<\/jats:title>\n Objectives<\/jats:title>\n The objective of this post hoc analysis was to analyze real-world dual antiplatelet therapy (DAPT) regimens following polymer-free sirolimus-eluting stent (PF-SES) implantations in an unselected patient population.<\/jats:p>\n <\/jats:sec>\n Methods<\/jats:title>\n Patient-level data from two all-comers observational studies (ClinicalTrials.gov<\/jats:ext-link> Identifiers: NCT02629575 and NCT02905214) were pooled and analyzed in terms of their primary endpoint. During the data verification process, we observed substantial deviations from DAPT guideline recommendations. To illuminate this gap between clinical practice and guideline recommendations, we conducted a post hoc analysis of DAPT regimens and clinical event rates for which we defined the net adverse event rate (NACE) consisting of target lesion revascularization (TLR, primary endpoint of all-comers observational studies) all-cause death, myocardial infarction (MI), stent thrombosis (ST), and bleeding events. A logistic regression was utilized to determine predictors why ticagrelor was used in stable coronary artery disease (CAD) patients instead of the guideline-recommended clopidogrel.<\/jats:p>\n <\/jats:sec>\n Results<\/jats:title>\n For stable CAD, the composite endpoint of clinical, bleeding, and stent thrombosis, i.e., NACE, between the clopidogrel and ticagrelor treatment groups was not different (5.4% vs. 5.1%, p<\/jats:italic>\u2009=\u20090.745). Likewise, in the acute coronary syndrome (ACS) cohort, the NACE rates were not different between both DAPT strategies (9.2% vs. 9.3%, p<\/jats:italic>\u2009=\u20090.927). There were also no differences in the accumulated rates for TLR, myocardial infarction ([MI], mortality, bleeding events, and stent thrombosis in elective and ACS patients. The main predictors for ticagrelor use in stable CAD patients were age <\u200965\u00a0years, smaller vessels, treatment of ostial and calcified lesions, and in-stent restenosis.<\/jats:p>\n <\/jats:sec>\n Conclusion<\/jats:title>\n Within the framework of a post hoc analysis based on a real-world, large cohort study, there were no differences in the combined endpoint of major adverse cardiac events (MACE), bleeding and thrombotic events for clopidogrel and ticagrelor in stable CAD or ACS patients. Despite the recommendation for clopidogrel by the European Society of Cardiology (ESC), real-world ticagrelor use was observed in subgroups of stable CAD patients that ought to be explored in future trials.<\/jats:p>\n <\/jats:sec>","DOI":"10.1007\/s10557-020-06963-5","type":"journal-article","created":{"date-parts":[[2020,3,24]],"date-time":"2020-03-24T13:02:45Z","timestamp":1585054965000},"page":"335-344","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Real-World Dual Antiplatelet Therapy Following Polymer-Free Sirolimus-Eluting Stent Implantations to Treat Coronary Artery Disease"],"prefix":"10.1007","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5965-8817","authenticated-orcid":false,"given":"Florian","family":"Krackhardt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Waliszewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viktor","family":"Ko\u010dka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petr","family":"Tou\u0161ek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bronislav","family":"Janek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Hudec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Lozano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koldobika Garcia-San","family":"Roman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno Garcia","family":"del Blanco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josepa","family":"Mauri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tay Mok","family":"Heang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tae Hoon","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myung Ho","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denny","family":"Herberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vjekoslav","family":"Tomulic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Levy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Sebagh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00f4me","family":"Rischner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Pansieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,3,24]]},"reference":[{"key":"6963_CR1","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1093\/eurheartj\/ehx419","volume":"39","author":"M Valgimigli","year":"2018","unstructured":"Valgimigli M, Bueno H, Byrne RA, Collet JP, Costa F, Jeppsson A, et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2018;39:213\u201360.","journal-title":"Eur Heart J"},{"key":"6963_CR2","doi-asserted-by":"publisher","first-page":"2608","DOI":"10.1093\/eurheartj\/ehv203","volume":"36","author":"RA Byrne","year":"2015","unstructured":"Byrne RA, Serruys PW, Baumbach A, Escaned J, Fajadet J, James S, et al. Report of a European Society of Cardiology-European Association of Percutaneous Cardiovascular Interventions task force on the evaluation of coronary stents in Europe: executive summary. Eur Heart J. 2015;36:2608\u201320.","journal-title":"Eur Heart J"},{"key":"6963_CR3","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.1056\/NEJMoa1503943","volume":"373","author":"P Urban","year":"2015","unstructured":"Urban P, Meredith IT, Abizaid A, Pocock SJ, Carri\u00e9 D, Naber C, et al. Polymer-free drug-coated coronary stents in patients at high bleeding risk. N Engl J Med. 2015;373:2038\u201347.","journal-title":"N Engl J Med"},{"key":"6963_CR4","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/S0140-6736(17)32713-7","volume":"391","author":"O Varenne","year":"2018","unstructured":"Varenne O, Cook S, Sideris G, Kedev S, Cuisset T, Carri\u00e9 D, et al. SENIOR investigators. Drug-eluting stents in elderly patients with coronary artery disease (SENIOR): a randomised single-blind trial. Lancet. 2018;391:41\u201350.","journal-title":"Lancet"},{"key":"6963_CR5","first-page":"1034","volume":"38","author":"T Palmerini","year":"2017","unstructured":"Palmerini T, Della Riva D, Benedetto U, Bacchi Reggiani L, Feres F, Abizaid A, et al. Three, six, or twelve months of dual antiplatelet therapy after DES implantation in patients with or without acute coronary syndromes: an individual patient data pairwise and network meta-analysis of six randomized trials and 11\u2009473 patients. Eur Heart J. 2017;38:1034\u201343.","journal-title":"Eur Heart J"},{"key":"6963_CR6","doi-asserted-by":"publisher","DOI":"10.1136\/openhrt-2017-000592","volume":"4","author":"F Krackhardt","year":"2017","unstructured":"Krackhardt F, Ko\u010dka V, Waliszewski MW, Utech A, Lustermann M, Hudec M, et al. Polymer-free sirolimus-eluting stents in a large-scale all-comers population. Open Heart. 2017;4:e000592 eCollection 2017.","journal-title":"Open Heart"},{"key":"6963_CR7","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1002\/ccd.27306","volume":"91","author":"F Krackhardt","year":"2018","unstructured":"Krackhardt F, Rosli MA, Leschke M, Schneider A, Sperling C, Heang TM, et al. Propensity score matched all comers population treated with ultra-thin strut bare metal and sirolimus-probucol coated drug-eluting stents of identical stent architecture. Catheter Cardiovasc Interv. 2018;91:1221\u20138.","journal-title":"Catheter Cardiovasc Interv"},{"key":"6963_CR8","doi-asserted-by":"publisher","first-page":"175394471982633","DOI":"10.1177\/1753944719826335","volume":"13","author":"C Sperling","year":"2019","unstructured":"Sperling C, Waliszewski MW, Kherad B, Krackhardt F. Comparative preclinical evaluation of a polymer-free sirolimus-eluting stent in porcine coronary arteries. Ther Adv Cardiovasc Dis. 2019;13:1753944719826335.","journal-title":"Ther Adv Cardiovasc Dis"},{"key":"6963_CR9","doi-asserted-by":"crossref","unstructured":"Sim DS, Jeong MH, Kim HS, et al. Clopidogrel versus aspirin after dual antiplatelet therapy in acute myocardial infarction patients undergoing drug-eluting stenting. Korean Circ J. 2019.","DOI":"10.4070\/kcj.2019.0166"},{"key":"6963_CR10","doi-asserted-by":"publisher","first-page":"2344","DOI":"10.1161\/CIRCULATIONAHA.106.685313","volume":"115","author":"DE Cutlip","year":"2007","unstructured":"Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es G, et al. Academic research consortium. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation. 2007;115:2344\u201351.","journal-title":"Circulation"},{"key":"6963_CR11","doi-asserted-by":"publisher","first-page":"2736","DOI":"10.1161\/CIRCULATIONAHA.110.009449","volume":"123","author":"R Mehran","year":"2011","unstructured":"Mehran R, Rao SV, Bhatt DL, Gibson CM, Caixeta A, Eikelboom J, et al. Standardized bleeding definitions for cardiovascular clinical trials. Circulation. 2011;123:2736\u201347.","journal-title":"Circulation"},{"key":"6963_CR12","doi-asserted-by":"publisher","first-page":"2541","DOI":"10.1093\/eurheartj\/ehu278","volume":"35","author":"S Windecker","year":"2014","unstructured":"Windecker S, Kolh P, Alfonso F, et al. 2014 ESC\/EACTS guidelines on myocardial revascularization: the task force on myocardial revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J. 2014;35:2541\u2013619.","journal-title":"Eur Heart J"},{"key":"6963_CR13","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1016\/j.jacc.2012.07.040","volume":"60","author":"J W\u00f6hrle","year":"2012","unstructured":"W\u00f6hrle J, Zadura M, M\u00f6bius-Winkler S, Leschke M, Opitz C, Ahmed W, et al. SeQuentPlease World Wide Registry: clinical results of SeQuent please paclitaxel-coated balloon angioplasty in a large-scale, prospective registry study. J Am Coll Cardiol. 2012;60:1733\u20138.","journal-title":"J Am Coll Cardiol"},{"key":"6963_CR14","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1002\/ccd.26261","volume":"88","author":"M Leschke","year":"2016","unstructured":"Leschke M, Waliszewski M, Pons M, Champin S, Nait Saidi L, Mok Heang T, et al. A.Thin strut bare metal stents in patients with atrial fibrillation: is there still a need for BMS? Catheter Cardiovasc Interv. 2016;88:358\u201366.","journal-title":"Catheter Cardiovasc Interv"},{"key":"6963_CR15","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/S0140-6736(17)32409-1","volume":"391","author":"SS Anand","year":"2018","unstructured":"Anand SS, Bosch J, Eikelboom JW, Connolly SJ, Diaz R, Widimsky P, et al. COMPASS investigators. Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet. 2018;391:219\u201329.","journal-title":"Lancet"},{"key":"6963_CR16","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1080\/14779072.2018.1435274","volume":"16","author":"P McKavanagh","year":"2018","unstructured":"McKavanagh P, Zawadowski G, Ahmed N, Kutryk M. The evolution of coronary stents. Expert Rev Cardiovasc Ther. 2018;16:219\u201328.","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"6963_CR17","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1111\/joic.12499","volume":"31","author":"M Baquet","year":"2018","unstructured":"Baquet M, Jochheim D, Mehilli J. Polymer-free drug-eluting stents for coronary artery disease. J Interv Cardiol. 2018;31:330\u20137.","journal-title":"J Interv Cardiol"},{"key":"6963_CR18","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.ahj.2019.04.017","volume":"214","author":"E Kedhi","year":"2019","unstructured":"Kedhi E, Latib A, Abizaid A, Kandzari D, Kirtane AJ, Mehran R, et al. Rationale and design of the Onyx ONE global randomized trial: a randomized controlled trial of high-bleeding risk patients after stent placement with 1 month of dual antiplatelet therapy. Am Heart J. 2019 Aug;214:134\u201341.","journal-title":"Am Heart J"},{"key":"6963_CR19","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1161\/CIRCULATIONAHA.111.078923","volume":"125","author":"M Pfisterer","year":"2012","unstructured":"Pfisterer M, Kaiser C, Jeger R. No one-size-fits-all: a tailored approach to antithrombotic therapy after stent implantation. Circulation. 2012;125:471\u20133.","journal-title":"Circulation"}],"updated-by":[{"DOI":"10.1007\/s10557-021-07290-z","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2022,7,22]],"date-time":"2022-07-22T00:00:00Z","timestamp":1658448000000}}],"container-title":["Cardiovascular Drugs and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-020-06963-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10557-020-06963-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-020-06963-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,22]],"date-time":"2022-07-22T06:09:32Z","timestamp":1658470172000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10557-020-06963-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,24]]},"references-count":19,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["6963"],"URL":"https:\/\/doi.org\/10.1007\/s10557-020-06963-5","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s10557-021-07290-z","asserted-by":"object"}]},"ISSN":["0920-3206","1573-7241"],"issn-type":[{"value":"0920-3206","type":"print"},{"value":"1573-7241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,24]]},"assertion":[{"value":"24 March 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2022","order":2,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":3,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":4,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s10557-021-07290-z","URL":"https:\/\/doi.org\/10.1007\/s10557-021-07290-z","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Prior to patient recruitment, all ethics votes were obtained from relevant national and\/or local ethics committees. In France, these non-interventional studies were approved by the Comit\u00e9 Consultative sur le Traitement de l\u2019Information en mati\u00e8re de Recherche dans le domaine de la Sant\u00e9<\/i> (CCTIRS dossier no. 14.613) and the Commission Nationale de l\u2019informatique et des Libert\u00e9s<\/i> (CNIL, demande d\u2019autorisation no. 915019). This trial was conducted according to the declaration of Helsinki in its most current form.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors provide a full disclosure of real or perceived conflicts of interests. Dr. Florian Krackhardt (honoraria speaker fees with B.Braun, AstraZeneca), Denny Herberger and Dr. Matthias Waliszewski (full-time employees B.Braun), all other authors: unrestricted research grant to recruit and document patients on a pay-by-patient basis. Co-authors of previously published DES studies with polymer-free sirolimus-eluting stents (all authors).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}